|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Translocation (9;11)(p21.3;q23.3) is one of the most common lysine methyltransferase 2A (KMT2A)-rearrangements in <i>de novo</i> and therapy-related acute myeloid leukemia (AML).
|
31807181 |
2019 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, we have established the MLL-SEPT2 gene fusion as the molecular abnormality subjacent to the translocation t(2;11)(q37;q23) in therapy-related acute myeloid leukemia.
|
19445675 |
2009 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The location of MLL translocation breakpoints within therapy-related acute myeloid leukemia linked to drugs targeting Topoisomerase II and infant acute leukemia (IAL) are biased toward the intron 11-exon 12 region of MLL, although lacking a comprehensive explanation.
|
19530238 |
2009 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.
|
18509329 |
2008 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The authors, herein, report a therapy-related acute myeloid leukemia with MLL-p300 fusion gene.
|
18778367 |
2008 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.
|
17854671 |
2007 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report on a case of therapy-related acute myeloid leukemia M2 showing a t(2;11)(q37;q23) and resulting in a new subtype of a MLL-SEPT2 chimeric transcript.
|
17574968 |
2007 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have identified a new mixed lineage leukemia (MLL) gene fusion partner in a patient with treatment-related acute myeloid leukemia (AML) presenting a t(2;11)(q37;q23) as the only cytogenetic abnormality.
|
16682951 |
2006 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Etoposide-induced treatment-related acute myelogenous leukemia (t-AML) is characterized by rearrangements of the mixed lineage leukemia (MLL) gene with one of its >50 partner genes, most probably as a consequence of etoposide-induced DNA double-strand breaks (DSBs).
|
16982737 |
2006 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is a clear clinical association between previous exposure to etoposide and therapy-related acute myeloid leukemia (t-AML) characterized by chromosomal rearrangements involving the mixed lineage leukemia (MLL) gene on chromosome band 11q23 [C.A.
|
16809075 |
2006 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report the first genomic map integrating translocation breakpoints and topoisomerase I, TOP2, and apoptotic DNA cleavage sites at nucleotide resolution across an MLL region harboring a t-AML translocation hotspot.
|
17033956 |
2006 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therapy-related acute myeloid leukemia 6 years after clonal detection of inv(11)(q21q23) and MLL gene rearrangement.
|
16720556 |
2006 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MLL/GAS7, resulting from t(11;17)(q23;p13), has been reported in one case of treatment-related acute myeloid leukemia (AML).
|
16956839 |
2006 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, whereas the genomic breakpoints in MLL tend to cluster in the 5' portion of the 8.3 kb breakpoint cluster region (BCR) in de novo and adult patients and in the 3' portion in infant leukemia patients and t-AML patients, those in both the AML1 and ETO genes occur in the same clustered regions in both de novo and t-AML patients.
|
16893685 |
2006 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion.
|
15528316 |
2005 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing.
|
14627986 |
2003 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
|
11753604 |
2001 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CBP gene at 16p13 fuses to MOZ and MLL as a result of the t(8;16)(p11;p13) in acute (myelo)monocytic leukemias (AML M4/M5) and the t(11;16)(q23;p13) in treatment-related AML, respectively.
|
11157802 |
2001 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies have shown that the 11q23 breakpoint in the t(11;19) rearrangement is consistent, and involves the MLL gene in t-AML patients.
|
11520560 |
2001 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS (GUANOSINE 5' MONOPHOSPHATE SYNTHETASE) gene.
|
11110714 |
2000 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GAS7 is a new partner gene of MLL in treatment-related acute myeloid leukemia.
|
10706619 |
2000 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The assay was validated by detection of the known fusion transcript and the transcript from the normal MLL allele in the cell line MV4-11. cDNA panhandle PCR then was used to identify the fusion transcripts in two cases of treatment-related acute myeloid leukemia where the karyotypes were normal and the partner genes unknown. cDNA panhandle PCR revealed a fusion of MLL with AF-10 in one case and a fusion of MLL with ELL in the other.
|
10920186 |
2000 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia.
|
10679915 |
2000 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we have identified a fusion partner of MLL in a 10-year-old female who developed therapy-related acute myeloid leukemia 17 months after treatment for Hodgkin's disease.
|
10339604 |
1999 |
|
Treatment related acute myeloid leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We recently demonstrated that 75% of de novo patient breakpoints in MLL mapped in the centromeric half of the BCR between two scaffold-associated regions (SAR), whereas 75% of the t-AML patient breakpoints mapped to the telomeric half of the BCR within a strong SAR.
|
9808573 |
1998 |